Empowered Patient Podcast

Karen Jagoda
  • 4.9 (19)
  • Medicine
  • Semiweekly

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

  1. 22h ago ·  Bonus

    Muscle Mass Assessment Reshaping Cancer Treatment Dosing and Survival Rate with Maureen McBeth ImpediMed TRANSCRIPT

    Maureen McBeth, Senior Manager of Clinical Research and Education at ImpediMed, discusses how sarcopenia, age-related muscle loss, significantly impacts the ability of cancer patients to tolerate treatment, yet has historically not been considered very relevant. ImpediMed has developed an FDA-cleared digital health platform that uses bioimpedance spectroscopy technology to provide rapid point-of-care analysis to identify muscle mass deficits and track the effectiveness of interventions. Frequent monitoring provides actionable data to personalize treatment dosing and optimize care.  Maureen explains, "So the Sozo digital health platform is what is called bioimpedance spectroscopy. So that's a mouthful. So we often pronounce it as BIS. And what this technology does is it takes 256 different frequencies, and it simultaneously scans your body. So in about 30 seconds, we can look at all the fluid in your body, and then that helps us estimate tissue outputs." "So by looking at the fluid, we can tell how much muscle you have or how much fat you have. And what's most important is that we're the only bioimpedance spectroscopy device that's FDA-cleared to assess things like body composition in healthy or unhealthy individuals. So this is not just a device for the gym. And furthermore, in August, we received our clearance from the FDA to help aid in the assessment of sarcopenia."  #ImpediMed #Sarcopenia #BreastCancer #Oncology #CancerSurvivorship  #BioimpedanceSpectroscopy #BodyComposition #ChemotherapyDosing #MuscleMassMatters #DigitalHealth #OncologyResearch #PrecisionMedicine #PatientEmpowerment ImpediMed.com  Listen to the podcast here

  2. 22h ago

    Muscle Mass Assessment Reshaping Cancer Treatment Dosing and Survival Rate with Maureen McBeth ImpediMed

    Maureen McBeth, Senior Manager of Clinical Research and Education at ImpediMed, discusses how sarcopenia, age-related muscle loss, significantly impacts the ability of cancer patients to tolerate treatment, yet has historically not been considered very relevant. ImpediMed has developed an FDA-cleared digital health platform that uses bioimpedance spectroscopy technology to provide rapid point-of-care analysis to identify muscle mass deficits and track the effectiveness of interventions. Frequent monitoring provides actionable data to personalize treatment dosing and optimize care.  Maureen explains, "So the Sozo digital health platform is what is called bioimpedance spectroscopy. So that's a mouthful. So we often pronounce it as BIS. And what this technology does is it takes 256 different frequencies, and it simultaneously scans your body. So in about 30 seconds, we can look at all the fluid in your body, and then that helps us estimate tissue outputs." "So by looking at the fluid, we can tell how much muscle you have or how much fat you have. And what's most important is that we're the only bioimpedance spectroscopy device that's FDA-cleared to assess things like body composition in healthy or unhealthy individuals. So this is not just a device for the gym. And furthermore, in August, we received our clearance from the FDA to help aid in the assessment of sarcopenia."  #ImpediMed #Sarcopenia #BreastCancer #Oncology #CancerSurvivorship  #BioimpedanceSpectroscopy #BodyComposition #ChemotherapyDosing #MuscleMassMatters #DigitalHealth #OncologyResearch #PrecisionMedicine #PatientEmpowerment ImpediMed.com Download the transcript here

  3. 4d ago ·  Bonus

    Healthcare Chatbots Become Action-Oriented Patient Navigation Tools with Jake McCarley Alluvium TRANSCRIPT

    Jake McCarley, Co-Founder and CEO of Alluvium, highlights how chatbots have evolved from simple question-and-answer functions to actively helping patients navigate complex health systems. The Alluvium platform integrates existing EMR systems with real-time information to provide intelligent patient support, helping patients reach the right site and provider and optimizing clinical resources. While chatbots offer advantages through memory and convenience, they remain best suited for tasks that don't require human judgment, such as automating administrative activities and streamlining access. Jake explains, "It's interesting how chatbots have evolved. I think they were originally more geared toward question-and-answer, which was an upgrade from the Google experience, where you had to go through all these hyperlinks and try to figure out what you were trying to solve for. So I think that was the initial experience, and they continue to evolve toward more action-oriented steps. I don't just want to know something interesting about what I'm looking for, like a dinner reservation or getting in to see a physician. I want to be able to actually take action on something from that chat experience. And so chat is evolving so I can take action on that, and I want to be able to interact with that chat consistently across my mobile device, my iPad, and my desktop. So it's really becoming a central point for how a consumer or a patient engages with most of what they're doing, which is kind of wild how fast that's happening."   "I think that interface just makes it easy because we're outsourcing some of the cognitive functions we would typically employ to make some of those decisions. So I think anything that's easy is generally popular. I think the second is memory. I think that's a huge difference between how traditional searches happened and just having a building context or an awareness of things you talked about before or things you've mentioned, and then taking those conversations and looping them into how it's going to process that discernment for the thing you're doing in the moment." #AlluviumHealth #HealthcareAI #PatientAccess #HealthTech #DigitalHealth #HealthcareLeadership #HealthSystemManagement #AIinHealthcare #PatientExperience #HealthIT #FutureOfHealthcare #Chatbots #HealthcareInnovation #HospitalManagement #RuralHealthcare #HealthcareStaffing  alluviumhealth.com Listen to the podcast here

  4. 4d ago

    Healthcare Chatbots Become Action-Oriented Patient Navigation Tools with Jake McCarley Alluvium

    Jake McCarley, Co-Founder and CEO of Alluvium, highlights how chatbots have evolved from simple question-and-answer functions to actively helping patients navigate complex health systems. The Alluvium platform integrates existing EMR systems with real-time information to provide intelligent patient support, helping patients reach the right site and provider and optimizing clinical resources. While chatbots offer advantages through memory and convenience, they remain best suited for tasks that don't require human judgment, such as automating administrative activities and streamlining access. Jake explains, "It's interesting how chatbots have evolved. I think they were originally more geared toward question-and-answer, which was an upgrade from the Google experience, where you had to go through all these hyperlinks and try to figure out what you were trying to solve for. So I think that was the initial experience, and they continue to evolve toward more action-oriented steps. I don't just want to know something interesting about what I'm looking for, like a dinner reservation or getting in to see a physician. I want to be able to actually take action on something from that chat experience. And so chat is evolving so I can take action on that, and I want to be able to interact with that chat consistently across my mobile device, my iPad, and my desktop. So it's really becoming a central point for how a consumer or a patient engages with most of what they're doing, which is kind of wild how fast that's happening."   "I think that interface just makes it easy because we're outsourcing some of the cognitive functions we would typically employ to make some of those decisions. So I think anything that's easy is generally popular. I think the second is memory. I think that's a huge difference between how traditional searches happened and just having a building context or an awareness of things you talked about before or things you've mentioned, and then taking those conversations and looping them into how it's going to process that discernment for the thing you're doing in the moment." #AlluviumHealth #HealthcareAI #PatientAccess #HealthTech #DigitalHealth #HealthcareLeadership #HealthSystemManagement #AIinHealthcare #PatientExperience #HealthIT #FutureOfHealthcare #Chatbots #HealthcareInnovation #HospitalManagement #RuralHealthcare #HealthcareStaffing  alluviumhealth.com Download the transcript here

  5. 5d ago ·  Bonus

    AI-Enabled Drug Discovery and Development for Rare Diseases with Dr. Christopher Moertel Healx TRANSCRIPT

    Dr. Christopher Moertel, Global Head of Clinical Development at Healx, describes how AI is transforming the discovery and development of treatments for rare diseases. Healx is using computational chemistry and AI to match disease pathways with existing compounds to identify drugs that may be repurposed or combined for new therapeutic applications. Bypassing the traditional laboratory model of drug development shows promise for accelerating the identification of treatments for conditions that have historically had few options. Christopher explains, "For many years, the pure focus was on AI development and developing it to a point where it could identify diseases and drugs that basically match one another. And it's just in the last two years that we've become a clinical-stage company. Our AI-enabled discoveries are now in the clinic with great hope for helping patients, and so far so good. We've assembled a clinical team now that is still smaller than our technology team, but it's obviously being felt by the organization. So it's been an exciting time for me having joined the organization just over a year ago and really watching the rapid growth of the clinical program whose genesis was in a computer."   "These are on-the-shelf medicines, of which there are thousands throughout the world. And so these medicines now are available in cyberspace, if you will. And what our company does that's different is we don't have a lab per se, as you would imagine it. We don't have rats and mice as you would imagine them. We have people who have degrees like computational chemists that is chemistry through a computer without any test tubes or beakers." "And we have all of the compounds that are out there, their structure. We have the defined chemical pathways that a lot of diseases take. And over time we've gone from DNA to RNA, now to chemistry, and have really seen how these chemical pathways could be exploited. And once they find a chemical pathway that we think is important in the disease process, then we go out and find compounds literally on the shelf that may influence that chemical pathway."   #HealxAi #RareDisease #NF1 #Neurofibromatosis #PediatricOncology #AIforGood  #DrugDiscovery #PatientVoice #Biotech#AIDrugDiscovery #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Biotech #PatientCare healx.ai Listen to the podcast here

  6. 5d ago

    AI-Enabled Drug Discovery and Development for Rare Diseases with Dr. Christopher Moertel Healx

    Dr. Christopher Moertel, Global Head of Clinical Development at Healx, describes how AI is transforming the discovery and development of treatments for rare diseases. Healx is using computational chemistry and AI to match disease pathways with existing compounds to identify drugs that may be repurposed or combined for new therapeutic applications. Bypassing the traditional laboratory model of drug development shows promise for accelerating the identification of treatments for conditions that have historically had few options. Christopher explains, "For many years, the pure focus was on AI development and developing it to a point where it could identify diseases and drugs that basically match one another. And it's just in the last two years that we've become a clinical-stage company. Our AI-enabled discoveries are now in the clinic with great hope for helping patients, and so far so good. We've assembled a clinical team now that is still smaller than our technology team, but it's obviously being felt by the organization. So it's been an exciting time for me having joined the organization just over a year ago and really watching the rapid growth of the clinical program whose genesis was in a computer."   "These are on-the-shelf medicines, of which there are thousands throughout the world. And so these medicines now are available in cyberspace, if you will. And what our company does that's different is we don't have a lab per se, as you would imagine it. We don't have rats and mice as you would imagine them. We have people who have degrees like computational chemists that is chemistry through a computer without any test tubes or beakers." "And we have all of the compounds that are out there, their structure. We have the defined chemical pathways that a lot of diseases take. And over time we've gone from DNA to RNA, now to chemistry, and have really seen how these chemical pathways could be exploited. And once they find a chemical pathway that we think is important in the disease process, then we go out and find compounds literally on the shelf that may influence that chemical pathway."   #HealxAi #RareDisease #NF1 #Neurofibromatosis #PediatricOncology #AIforGood  #DrugDiscovery #PatientVoice #Biotech#AIDrugDiscovery #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Biotech #PatientCare healx.ai Download the transcript here

  7. 5d ago ·  Bonus

    Targeting the CLEVER-1 Receptor to Treat Higher Risk MDS with Dr. Aneel Nimba Faron Pharmaceuticals TRANSCRIPT

    Dr. Aneel Nimba, Medical Director at Faron Pharmaceuticals,  discusses the company's innovative approach to treating higher risk myelodysplastic syndromes, a group of rare blood cancers, with its lead drug candidate that targets the CLEVER-1 receptor which controls the tumor microenvironment. This first-in-class monoclonal antibody stimulates the immune system, directly affects abnormal blast cell metabolism and stimulates bone marrow. When combined with limited current treatments, clinical data are showing a path to transform a life-threatening disease into a manageable chronic condition.  Aneel explains, "The main target that we're essentially going for in cancer at Faron is a target called CLEVER-1, and that stands for common lymphatic endothelium vascular receptor one. But essentially, it's a target that hasn't been looked at before. The team at Faron has been working on it for the last 20 years, and we're learning more and more now that it's involved in controlling the tumor. "    "That's important because it also helps with what we call this concept of synergy with other anti-cancer drugs and helps them do their job better at killing cancer. But there are so many other things that CLEVER-1 is involved in downstream within the cells, particularly in higher risk myelodysplastic syndromes or HR-MDs. And so it's truly what we call a first-in-class drug. And I'm quite fascinated with the data that's coming out. I mean, I joined Faron about 16 months ago, and it's definitely an interesting target, not only in blood cancers, but also has the potential in solid tumors." #FaronPharmaceuticals #Bexmarilimab #Hematology #MyelodysplasticSyndrome #BloodCancer #ClinicalTrials #ImmunoOncology #HMA #Azacitidine #BoneMarrowFailure #GeriatricOncology #PrecisionMedicine #IPSSM #CLEVER1 #MonoclonalAntibody #FDA #EHA2024 #MDS #HRMDS #CancerResearch #NovelImmunotherapy  Faron.com Listen to the podcast here

  8. 5d ago

    Targeting the CLEVER-1 Receptor to Treat Higher Risk MDS with Dr. Aneel Nimba Faron Pharmaceuticals

    Dr. Aneel Nimba, Medical Director at Faron Pharmaceuticals,  discusses the company's innovative approach to treating higher risk myelodysplastic syndromes, a group of rare blood cancers, with its lead drug candidate that targets the CLEVER-1 receptor which controls the tumor microenvironment. This first-in-class monoclonal antibody stimulates the immune system, directly affects abnormal blast cell metabolism and stimulates bone marrow. When combined with limited current treatments, clinical data are showing a path to transform a life-threatening disease into a manageable chronic condition.  Aneel explains, "The main target that we're essentially going for in cancer at Faron is a target called CLEVER-1, and that stands for common lymphatic endothelium vascular receptor one. But essentially, it's a target that hasn't been looked at before. The team at Faron has been working on it for the last 20 years, and we're learning more and more now that it's involved in controlling the tumor. "    "That's important because it also helps with what we call this concept of synergy with other anti-cancer drugs and helps them do their job better at killing cancer. But there are so many other things that CLEVER-1 is involved in downstream within the cells, particularly in higher risk myelodysplastic syndromes or HR-MDs. And so it's truly what we call a first-in-class drug. And I'm quite fascinated with the data that's coming out. I mean, I joined Faron about 16 months ago, and it's definitely an interesting target, not only in blood cancers, but also has the potential in solid tumors." #FaronPharmaceuticals #Bexmarilimab #Hematology #MyelodysplasticSyndrome #BloodCancer #ClinicalTrials #ImmunoOncology #HMA #Azacitidine #BoneMarrowFailure #GeriatricOncology #PrecisionMedicine #IPSSM #CLEVER1 #MonoclonalAntibody #FDA #EHA2024 #MDS #HRMDS #CancerResearch #NovelImmunotherapy  Faron.com Download the transcript here

See All (2K)

4.9
out of 5
19 Ratings

About

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. The show covers such topics as aging in place, innovative uses for wearables and sensors, advances in clinical research, applied genetics, drug development, and challenges for connected health entrepreneurs.

Information

You Might Also Like